AB0763 THE INFLUENCE OF OBESITY ON BIOLOGICAL DMARD TREATMENT RESPONSE IN PSORIATIC ARTHRITIS: HUR-BIO REAL LIFE RESULTS

Abstract

Background:Obesity could be a risk factor for response to treatment and disease severity in psoriatic arthritis (PsA) because of potential pro-inflammatory effects of cytokines produced by adipose tissue (1).Objectives:This study aimed to assess association of demographic, clinical and disease activity indices with obesity in patients using biological disease-modifying antirheumatic drugs (bDMARD) treatment in HUR-BIO cohort.Methods:HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a prospective, single center database of biological treatments since 2005. Until January 2020, HUR-BIO PsA registry enrolled 469 patients. Demographic, clinical, laboratory, therapeutic data were collected from this database which including tender/swollen joint counts, Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), Health Assessment Questionnaire (HAQ), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Disease Activity Score - 28 joint (DAS28), Disease Activity index for Psoriatic Arthritis - 28 joint score (DAPSA-28), Psoriatic Arthritis Impact of Disease 12-item questionnaire (PSAID-12). BMI≥30 was defined as obesity.Results:HUR-BIO PsA had 469 PsA patients and 441 patients with available BMI data were enrolled. Overall, 187/441 patients (42%) had obesity. The median follow-up period of obese and non-obese PsA patients was 7 (3-12) and 8 (4-12) years, respectively (p: 0.31). Obese patients were older at the age of PsA diagnosis (43 (33 - 53) vs 36 (28 – 45) years, p<0.001), higher female gender (76% vs 64%, p: 0.008), higher comorbidities (53% vs 27%, p<0.001). While there was no difference between the two groups in uveitis, IBD, family history and smoking; HLA-B27 was higher in non-obese patients (table). DAS28, BASDAI, DAPSA-28 joints, PSAID-12 were higher in the obese group than in the non-obese group, both before the biological DMARD and at the last visit (p <0.05) (figure 1). BASDAI50% response were similar and patients with HAQ score <0.5 were less frequently in obese patients. For obese and non-obese PsA patients, first bDMARDs percentages were adalimumab 46 vs 48, etanercept 18.2 vs 17, infliximab 14 vs 18, golimumab 7 vs 7.5, certolizumab 12 vs 7, secukinumab 1 vs 0.5, ustekinumab 1 vs 1, others 1 vs 1%, respectively and were similar (p: 0.72). Retention rate for first bDMARD was higher in non-obese than obese patients. Median of the retention rate of bDMARD in obese and non-obese groups was 54.2 and 79, respectively (log rank p: 0.03) (figure 2).Conclusion:Obesity was associated with higher disease activity and poorer effect of bDMARD treatment in patients with PsA. In obese PsA patients with high disease activity despite bDMARD therapy, intentional weight loss may be recommended as an adjunctive therapy.